Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Mar;42(3):372-8.
doi: 10.3899/jrheum.140853. Epub 2015 Jan 15.

Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapy

Kalle Jyri Aaltonen  1 , Jaana Tuulikki Joensuu  2 , Liisa Virkki  2 , Tuulikki Sokka  2 , Pasi Aronen  2 , Heikki Relas  2 , Heikki Valleala  2 , Vappu Rantalaiho  2 , Laura Pirilä  2 , Kari Puolakka  2 , Tea Uusitalo  2 , Marja Blom  2 , Yrjö Tapio Konttinen  2 , Dan Nordström  2
Affiliations

Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapy

Kalle Jyri Aaltonen et al. J Rheumatol. 2015 Mar.

Abstract

Objective: Because of the role of tumor necrosis factor (TNF) in host defense, it was hypothesized that its inhibition might lead to an increased risk of malignancies and infections. The objective of our study was to assess the incidence of serious infections leading to hospitalization and malignancies among patients with rheumatoid arthritis (RA) receiving either TNF inhibitor or rituximab (RTX) therapy.

Methods: The study population was identified from the National Register for Biologic Treatment in Finland and the hospital records of Central Finland Central Hospital for conventional disease-modifying antirheumatic drug (cDMARD) users. Data on infections and malignancies were acquired from national healthcare registers. A Poisson model was used to calculate the adjusted incidence rate ratios (aIRR) and was composed of age, sex, time from diagnosis, year of the beginning of the followup, rheumatoid factor status, Disease Activity Score at 28 joints, Health Assessment Questionnaire, prior malignancy, prior serious infection, prior biologic use, and time-updated use of methotrexate, sulfasalazine, hydroxychloroquine, and oral corticosteroids as confounders.

Results: In total, during the followup of 10,994 patient-years, 92 malignancies and 341 serious infections were included in the analyses. The aIRR of infections compared to cDMARD users were 1.2 (95% CI 0.63-2.3), 0.84 (95% CI 0.53-1.3), 0.98 (95% CI 0.60-1.6), and 1.1 (95% CI 0.59-1.9) for the patients treated with infliximab (IFX), etanercept, adalimumab, and RTX, respectively. The crude rates of malignancies were highest among the users of cDMARD and RTX, and lowest among patients treated with IFX with no differences in aIRR.

Conclusion: Our results provide some reassurance of the safety of biologic treatments in the treatment of RA.

Keywords: ANTIBODIES; EPIDEMIOLOGY; INFECTION; MONOCLONAL; NEOPLASMS; RHEUMATOID ARTHRITIS.

PubMed Disclaimer

MeSH terms

LinkOut - more resources